Please assess the completion status of the following clinical trial:

Trial Title: A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naive (no prior treatment with IFN-a +/- RBV regimens.~* Subjects who have discontinued IFN-a containing regimens after \<2 weeks of therapy due to tolerability issues are considered treatment naive.~* HCV RNA \> 100,000 IU/mL at screening.~* Genotype 1.~* A diagnosis of chronic HCV infection for at least 6 months.~Exclusion Criteria:~* Evidence of acute or chronic infection with HIV or HBV.~* Exposure within the previous three months to an investigational anti-HCV agent.~* Evidence of severe or decompensated liver disease.~* Subjects with liver disease unrelated to HCV infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 500 mg BID
- B (Type: EXPERIMENTAL): 300 mg BID
- C (Type: EXPERIMENTAL): 200 mg BID
- D (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).